| Outcome Measures: |
Primary: AUC0-inf, Area Under the Concentration-time curve from time zero to infinite time, -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration|AUC0-t, Area Under the Concentration-time curve from time zero to the last measurable concentration, -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration|Cmax, Maximum concentration of the active substance in the blood plasma of participants during the observation period, -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration | Secondary: AUC_%Extrap, Extrapolated Part Percentage of AUC0-inf, -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration|Tmax, Time of maximum concentration observed, -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration|t 1/2, Elimination half life, -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration|λz, The Volume of Distribution at Terminal Phase, -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration|CL, Clearance Rate, -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration|Safety and Immunogenicity, Adverse events and positive rate of anti-drug antibodies, AEs will be collected after assigning the ICF. Immunogenicity sample will be collected at -60 minutes and 336、840 hours after administration.
|
